By contrast, blocking DKK1 did not affect inflammation but led to cartilage and bone formation in inflamed joints. This report is the first to suggest a cellular and molecular mechanism underlying ...

As a result of the study, we identified the mechanism by which FLT3L activates the STAT3-DKK1 pathway and inhibits the WNT signaling pathway involved in bone formation. Furthermore, this mechanism ...

In MSS colorectal cancer, sirexatamab's combo therapy showed a 32% higher ORR, 3.5-month longer PFS in high DKK1 patients vs. control. Patients without prior anti-VEGF therapy saw a 22% higher ORR ...